Technology Overview

Treatment with small-molecules targeting Histone Deacetylase 3 (HDAC3) can enhance re-myelination and functional nerve recovery in the central and peripheral nerve systems (CNS and PNS) in animal models of multiple sclerosis and peripheral neuropathy. Targeting HDAC3 with these inhibitors also rejuvenates the age-related decline in functional recovery after injury.

Applications

• Inhibiting histone deacetylase 3 may be used to treat demyelinating diseases.
• Histone deacetylase 3 inhibitors promote myelin repair and nerve regeneration after injury.

Market Overview

The most common demyelinating disease is Multiple Sclerosis (MS). More than 2.3 million people worldwide are affected by MS. Other myelination related neural disorders include Alzheimer’s disease, Parkinson’s disease, Huntington disease, and amyotrophic lateral sclerosis (ALS).

Investigator Overview

Qing (Richard) Lu, PhD., Division of Experimental Hematology and Cancer Biology